

DAFTAR PUSTAKA

- Ackerson, T., Adeoye, O. M., Brown, M., Demaerschalk, B. M., Hoh, B., Leslie-mazwi, T. M., Ovbiagele, B., Scott, P. A., Sheth, K. N., Southerland, A. M., & Summers, D. V. (2018). *AHA / ASA Guideline 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke*. <https://doi.org/10.1161/STR.000000000000158>
- Aditya Prayoga, & Rasyid, Z. (2022). Determinan Kejadian Stroke Iskemik Pasien Rawat Inap di RSUD Petala Bumi Provinsi Riau Tahun 2019. *Jurnal Kesehatan Komunitas*, 8(1), 52–58. <https://doi.org/10.25311/keskom.vol8.iss1.640>
- Adnan I. Qureshi, Malik M. Adil, H. Z. and M. F. K. S. (2013). *Factors Associated With Length of Hospitalization in Patients Admitted With Transient Ischemic Attack in United States*. <https://doi.org/10.1161/STROKEAHA.111.000590>
- Agustina, H. (2021). *Identifikasi Drug Related Problems (DRPs) Terhadap Pengobatan Pasien Stroke Iskemik Di Instalasi Rawap Inap Rumah Sakit Umum Pusat (RSUP) Fatmawati Tahun 2019*.
- American Pharmacists Association. (2016). Drug Information Handbook 21st. In *Lexicomp* (21th ed., Vol. 6, Issue August).
- Amran. (2012). *Analisis Faktor Risiko Kematian Penderita Stroke*.
- Anggraini, R., Ayu, W. D., & Masruhim, M. A. (2016). *Terapi Penggunaan Obat Stroke Pada Pasien Stroke Iskemik Di Rsud Abdul Wahab Sjahrane Samarinda. April 2016*, 89–97. <https://doi.org/10.25026/mpc.v3i1.71>
- D, W., H, S., & MG, T. (2018). Karakteristik Penderita Stroke Iskemik Yang Dirawat Inap di Rumah Sakit Tk II Putri Hijau Medan Kesdam I/Bukit Barisan Tahun 2015. *Universitas Sumatera Utara*, 1, 4.
- Dini Setya Praja, Hasmono, D., & Syifa, N. (2013). Studi Penggunaan Obat Neuroprotektan Pada Pasien Stroke Iskemik (Penelitian Di Rumah Sakit Umum Dr. Saiful Anwar Malang). *Pharmacy*, 10(02).
- Drugs.com. (2023a). *Drug Interaction Report 1*. https://www.drugs.com/interactions-check.php?drug_list=133-0,172-0,393-0,1257-0,1937-0,2221-0,2288-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]
- Drugs.com. (2023b). *Drug Interaction Report 10*. https://www.drugs.com/interactions-check.php?drug_list=172-0,810-0,1415-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate

e&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023c). *Drug Interaction Report 11*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,487-0,3350-0,862-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023d). *Drug Interaction Report 12*.

https://www.drugs.com/interactions-check.php?drug_list=1015-0,3613-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023e). *Drug Interaction Report 13*.

https://www.drugs.com/interactions-check.php?drug_list=393-0,1146-0,1790-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023f). *Drug Interaction Report 14*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,393-0,1257-0,1790-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023g). *Drug Interaction Report 15*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,1310-0,1991-0,2288-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023h). *Drug Interaction Report 16*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,1415-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023i). *Drug Interaction Report 17*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,1549-0,1607-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023j). *Drug Interaction Report 18.*

https://www.drugs.com/interactions-check.php?drug_list=276-0,705-0,3613-0,1750-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023k). *Drug Interaction Report 19.*

https://www.drugs.com/interactions-check.php?drug_list=1457-0,1752-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023l). *Drug Interaction Report 2.*

https://www.drugs.com/interactions-check.php?drug_list=172-0,276-0,393-0,481-0,3350-0,1549-0,2221-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023m). *Drug Interaction Report 20.*

https://www.drugs.com/interactions-check.php?drug_list=3613-0,1790-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023n). *Drug Interaction Report 21.*

https://www.drugs.com/interactions-check.php?drug_list=172-0,3350-0,862-0,1863-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023o). *Drug Interaction Report 22.*

https://www.drugs.com/interactions-check.php?drug_list=1415-0,3613-0,11-2744,1863-0,1991-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023p). *Drug Interaction Report 23.*

https://www.drugs.com/interactions-check.php?drug_list=1937-0,2221-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023q). *Drug Interaction Report 24.*

https://www.drugs.com/interactions-check.php?drug_list=1937-0,2288-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 5 Mei 2023]

Drugs.com. (2023r). *Drug Interaction Report 3*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,243-0,487-0,705-0,1015-0,1549-0,1607-0,1750-0,2288-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023s). *Drug Interaction Report 4*.

https://www.drugs.com/interactions-check.php?drug_list=276-0,705-0,1015-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023t). *Drug Interaction Report 5*.

https://www.drugs.com/interactions-check.php?drug_list=557-0,1146-0,1863-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023u). *Drug Interaction Report 6*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,300-0,393-0,639-0,1257-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023v). *Drug Interaction Report 7*.

https://www.drugs.com/interactions-check.php?drug_list=393-0,704-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023w). *Drug Interaction Report 8*.

https://www.drugs.com/interactions-check.php?drug_list=705-0,1015-0,1310-0,1790-0,2221-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1 [Diakses pada 4 Mei 2023]

Drugs.com. (2023x). *Drug Interaction Report 9*.

https://www.drugs.com/interactions-check.php?drug_list=172-0,718-0,1863-0&types%5B%5D=major&types%5B%5D=minor&types%5B%5D=moderate&types%5B%5D=food&types%5B%5D=therapeutic_duplication&professional=1

onal=1 [Diakses pada 4 Mei 2023]

- G. Wells, B., T. DiPiro, J., L. Schwinghammer, T., & DiPiro, C. V. (2015). *Pharmacotherapy Handbook Ninth Edition* (9th ed.). Medical.
- Grieb, P. (2014). Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. *CNS Drugs*, 28(3), 185–193. <https://doi.org/10.1007/s40263-014-0144-8>
- Harisi, H. (2019). *Kajian Drug Related Problems (DRPs) pada Pasien Stroke Iskemik dan Pengaruhnya Terhadap Outcome Klinik di Instalasi Rawat Inap RSUD Budhi Asih Tahun 2018*.
- Hisni, D., Evelianti Saputri, M., & Sujarni. (2022). Stroke Iskemik Di Instalasi Fisioterapi Rumah Sakit Pluit Jakarta Utara Periode Tahun 2021. *Penelitian Keperawatan Kontemporer*, 2(1), 140–149.
- Inayah, N., Manggau, M. A., & Amran, Y. (2019). Analisis Efektivitas Dan Efek Samping Penggunaan Clopidogrel Tunggal Dan Kombinasi Clopidogrel-Aspilet Pada Pasien Stroke Iskemik Di Rsup Dr.Wahidin Sudirohusodo Makassar. *Majalah Farmasi Dan Farmakologi*, 22(3), 81–84. <https://doi.org/10.20956/mff.v22i3.5811>
- Islam, Z. (2018). *Evaluasi Penggunaan Obat Pada Pasien Stroke Dengan Hipertensi Rawat Inap Di Rumah Sakit Islam Jakarta Pondok Kopi Tahun 2016*. 4, 978–979.
- J, Misbach., W, A. (2001). Stroke in Indonesia: a first large prospective hospital-based study of acute stroke in 28 hospitals in Indonesia. *Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia*, 8(3), 245–249. <https://doi.org/https://doi.org/10.1054/jocn.1999.0667>
- Jasielski, P., Piędel, F., Piwek, M., Rocka, A., Petit, V., & Rejdak, K. (2020). Application of citicoline in neurological disorders: A systematic review. *Nutrients*, 12(10), 1–20. <https://doi.org/10.3390/nu12103113>
- JNC 8. (2014). Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *JAMA*, 311 (5).
- Junaidi, dr. I. (2011). *Stroke waspadai ancamannya* (D. D. Tandung (ed.)). Penerbit Andi Yogyakarta.
- Juwita, D., Almasdy, D., & Hardini, T. (2018). Evaluation of Antihypertensive Drug Use on Ischemic Stroke Patients at National Stroke Hospital Bukittinggi. *Indonesian Journal of Clinical Pharmacy*, 7(2), 99–107. <https://doi.org/10.15416/ijcp.2018.7.2.99>

- Kemendes. (2019). *Keputusan Menteri Kesehatan Republik Indonesia Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Stroke*. 1–151.
- Kementerian Kesehatan RI. (2019). Laporan Provinsi Jawa Barat, Riskesdas 2018. In *Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan*.
- Khairatunnisa, S. D. M. (2017). Faktor Risiko yang Berhubungan dengan Kejadian Stroke pada Pasien di RSUD H. Sahudin Kutacane Kabupaten Aceh Tenggara. *Faktor Risiko Yang Berhubungan Dengan Kejadian Stroke Pada Pasien Di RSUD H. Sahudin Kutacane Kabupaten Aceh Tenggara*, 2(1).
- Kocsis, B. J., & Scher, L. M. (2015). Pharmacotherapy. In *Borderline Personality Disorder in Older Adults: Emphasis on Care in Institutional Settings*.
- Laily, R. S. (2017). Hubungan Karakteristik Penderita dan Hipertensi dengan Kejadian Stroke Iskemik. *Jurnal Berkala Epidemiologi*, 5(1), 48–59. <https://doi.org/10.20473/jbe.v5i1>.
- Madill, K. (2004). Standards association of australia. *Australian Surveyor*, 4(7), 426. <https://doi.org/10.1080/00050326.1933.10436323>
- Meila, O., & Rochana, H. I. (2017). Kajian Drug Related Problems (DRPs) Terhadap Pengobatan Pasien Stroke Iskemik di Rumah Sakit Pusat Otak Nasional Jakarta Periode Januari – Desember 2015 Study of Drug Related Problems (DRPs) to Treatment of Patient with Ischemic Stroke at National Bra. *Pharmacon: Jurnal Farmasi Indonesia*, 14(2), 48–53.
- Ming Zhang, Wenjuan Han, Sanjue Hu, H. X. (2013). *Methylcobalamin: A Potential Vitamin of Pain Killer. Neural Plasticity*.
- Notoatmodjo, S. (2007). *Promosi Kesehatan dan Ilmu Perilaku*. Rineka Cipta.
- Nuryati. (2017). *Farmakologi RMIK*. Kementerian Kesehatan Republik Indonesia.
- PCNE. (2017). *Pharmaceutical Care Network Europe v9 . 00*. 9–10. https://www.pcne.org/upload/files/435_FINAL_Pharmaceutical_Care_Network_Europe_v9.00_-_Bahasa_Indonesia.pdf
- PERDOSSI. (2011). Pedoman Penatalaksanaan Stroke. *Pokdi Stroke*.
- Permenkes. (2019). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2019 Tentang Penerapan Manajemen Risiko Terintegrasi Di Lingkungan Kementerian Kesehatan*. 5–10.
- Permenkes. (2020). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 3 Tahun 2020 Tentang Klasifikasi Dan Perizinan Rumah Sakit*. 3, 1–80.
- Permenkes. (2022). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 24 Tahun 2022 Tentang Rekam Medis*. 1–20.

- Purnama, S. D., Pambudi, P., & Al Audhah, N. (2013). Perbandingan Efektivitas Asetosal Dan Kombinasi Asetosal-Klopidogrel Terhadap Pasien Stroke Iskemik Akut. *Jurnal Berkala Kedokteran*, 9.
- Rachmina, D. (2021). Ruang Lingkup, Konteks, Kriteria Manajemen Risiko – Kriteria Risiko. *IRMAPA*. <https://irmapa.org/ruang-lingkup-konteks-kriteria-manajemen-risiko-kriteria-risiko/> [Diakses pada 11 Juli 2023]
- Rahmadani, E., & Rustandi, H. (2018). Gambaran Drug Related Problems (DRP's) pada Penatalaksanaan Pasien Stroke Hemoragik dan Stroke Non Hemoragik di RSUD Dr M Yunus Bengkulu. *Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia*, 5(1), 36–44.
- Rahmat, A. (2016). Post-Power Syndrome Dan Perubahan. *Psymphatic*, 3(1), 77–94.
- Robert, M. M. J., Bonny, S. F., & Sopotan. M.E Gabby. (2014). Manajemen Risiko Kesehatan Dan Keselamatan Kerja (K3) (Study Kasus Pada Pembangunan Gedung Sma Eben Haezar). *Jurnal Ilmiah Media Engineering*, 4(4), 229–238.
- Saraswati, D, R. (2021). Transisi Epidemiologi Stroke Sebagai Penyebab Kematian Pada Semua Kelompok Usia Di Indonesia. *Journal Kedokteran*, 2(1), 81–86. <https://conference.upnvj.ac.id/index.php/sensorik/article/view/1001>
- Saxena, A., & Prasad, R. N. (2016). Factors Predicting Length of Hospital Stay in Acute Stroke Patients Admitted in a Rural Tertiary Care Hospital. *Journal of Gerontology & Geriatric Research*, 01(s5). <https://doi.org/10.4172/2167-7182.s5-003>
- Saxena, T., Ali, A. O., & Saxena, M. (2018). Pathophysiology of essential hypertension: an update. *Expert Review of Cardiovascular Therapy*, 16:12, 879–887. <https://doi.org/10.1080/14779072.2018.1540301>
- Solang, N. G., Wiyono, W. I., & Mpila, D. A. (2021). Identification of Potential Drug Interactions of Stroke Patients Identifikasi Interaksi Obat Potensial Pada Pasien. *Pharmacon*, 10, 639–648.
- Tahir, R. W. M., Rija'i, H. R., & Indriyanti, N. (2021). Kajian Efektivitas Pengobatan pada Pasien Stroke Iskemik di Instalasi Rawat Inap RSUD Nunukan. *Proceeding of Mulawarman Pharmaceuticals Conferences*, 14, 254–261. <https://doi.org/10.25026/mpc.v14i1.581>
- Togu, G. M., Lisda Amalia, & Trully Deti Rose Sitorus. (2021). Pola Pengobatan Stroke Iskemik Pada Pasien Lansia di Rumah Sakit Hasan Sadikin Bandung. *Journal Of The Indonesian Medical Association*, 71(2), 65–70. <https://doi.org/10.47830/jinma-vol.71.2-2021-387>
- Tuti Wiyati, Rizki Laela Ramdani, N. W. (2020). Potensi Interaksi Obat Pada

Pasien Stroke Iskemik Rawat Inap Di Salah Satu Rs Di Jakarta. *Fakultas Farmasi, Universitas Muhammadiyah, Prof Hamka, Jakarta Timur.*, xx(xx).

Wa, W. (2011). *Strategi Mengatasi Dan Bangkit Dari Stroke*. Pustaka Pelajar.

Wahyuni, A. T. (2019). Profil Terapi Pasien Stroke Iskemik Di Instalasi Rawat Jalan Rumah Sakit Umum Pindad Turen. 2019, 1–13.

Yusuf, F. (2016). Studi Perbandingan Obat Generik Dan Obat Dengan Nama Dagang. *Jurnal Farmanesia*, 147(March), 11–40.

